Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;10(9):973-982.
doi: 10.1002/psp4.12681. Epub 2021 Aug 1.

Anti-SARS-CoV-2 Repurposing Drug Database: Clinical Pharmacology Considerations

Xinyuan Zhang  1 , Yuching Yang  1 , Manuela Grimstein  1 , Guansheng Liu  1 , Eliford Kitabi  1 , Jianghong Fan  1 , Ying-Hong Wang  1 , Justin Earp  1 , James L Weaver  1 , Hao Zhu  1 , Jiang Liu  1 , Kellie S Reynolds  1 , Shiew-Mei Huang  1 , Yaning Wang  1
Affiliations
Review

Anti-SARS-CoV-2 Repurposing Drug Database: Clinical Pharmacology Considerations

Xinyuan Zhang et al. CPT Pharmacometrics Syst Pharmacol. 2021 Sep.

Abstract

A critical step to evaluate the potential in vivo antiviral activity of a drug is to connect the in vivo exposure to its in vitro antiviral activity. The Anti-SARS-CoV-2 Repurposing Drug Database is a database that includes both in vitro anti-SARS-CoV-2 activity and in vivo pharmacokinetic data to facilitate the extrapolation from in vitro antiviral activity to potential in vivo antiviral activity for a large set of drugs/compounds. In addition to serving as a data source for in vitro anti-SARS-CoV-2 activity and in vivo pharmacokinetic information, the database is also a calculation tool that can be used to compare the in vitro antiviral activity with in vivo drug exposure to identify potential anti-SARS-CoV-2 drugs. Continuous development and expansion are feasible with the public availability of this database.

PubMed Disclaimer

Conflict of interest statement

The authors declared no competing interests for this work.

Figures

FIGURE 1
FIGURE 1
Illustration of database construction and utility. ADME, absorption, distribution, metabolism, and excretion; CC50, the drug concentration that reduces the total cell number by 50% values; EC50, the drug concentration that inhibits 50% of the virus; EC90, the drug concentration that inhibits 90% of the virus; fup, unbound fraction in plasma; MW, molecular weight; PK, pharmacokinetic
See this image and copyright information in PMC

References

    1. Fan J, Zhang X, Liu J, et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating patients with coronavirus disease 2019. Clin Infect Dis. 2020;71(12):3232–3236. 10.1093/cid/ciaa623 - DOI - PMC - PubMed
    1. Boffito M, Back DJ, Flexner C, et al. Toward consensus on correct interpretation of protein binding in plasma and other biological matrices for COVID‐19 therapeutic development. Clin Pharmacol Ther. 2021;110(1):64–68. 10.1002/cpt.2099 - DOI - PMC - PubMed
    1. NDA 021567 atazanavir USPI. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021567s044,206.... Published 2020. Accessed December 9, 2020.
    1. Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS‐CoV‐2 from FDA‐approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819‐20. 10.1128/AAC.00819-20 - DOI - PMC - PubMed
    1. Fintelman‐Rodrigues N, Sacramento CQ, Ribeiro Lima C, et al. Atazanavir, alone or in combination with ritonavir, inhibits SARS‐CoV‐2 replication and proinflammatory cytokine production. Antimicrob Agents Chemother. 2020;64. 10.1128/AAC.00825-20 - DOI - PMC - PubMed

MeSH terms

Substances